Peptides for Weight Loss: What Actually Has Evidence

Search "peptides for weight loss" and you'll get two completely different worlds in the same results: FDA-approved drugs that produce some of the largest weight loss ever recorded outside surgery, and a gray market of vials marketed with before-and-after photos and very little human data. Both are technically "peptides." The difference between them is the whole story.

Here's the short version. The peptides that work for weight loss are the GLP-1 and GIP receptor agonists — semaglutide and tirzepatide — and they're peptides. Most of the compounds sold online as "weight-loss peptides" (AOD-9604, HGH fragment 176-191, and the growth-hormone secretagogues) have weak, narrow, or failed evidence for fat loss specifically. This page sorts them into tiers by what the evidence actually shows.

Quick Reference: The Evidence Tiers

Tier 1: The Peptides That Actually Work (GLP-1 / GIP)

This is the answer most people are looking for, whether they realize it or not. Semaglutide and tirzepatide are peptides — synthetic chains of amino acids engineered to mimic the gut hormones GLP-1 and GIP, which regulate appetite, satiety, and blood sugar. They slow gastric emptying and reduce appetite, and the weight-loss results are not subtle.

• Semaglutide (sold as Wegovy for weight management, Ozempic for diabetes) produced an average of about 15% body-weight loss at 68 weeks in the STEP 1 trial.
• Tirzepatide (Zepbound for weight management, Mounjaro for diabetes) produced about 22.5% at the 15 mg dose over 72 weeks in SURMOUNT-1 — the highest of any approved medication.

These are prescription drugs with a defined titration schedule, real side-effect profiles, and quality control. If you're on one or considering one, the dosing schedules are laid out in the semaglutide dosage chart and the tirzepatide dose chart, and the mechanism behind them is in the semaglutide guide and tirzepatide guide.

The practical point: if the question is "do peptides work for weight loss," the strongest evidence in the entire category belongs to the two drugs people don't usually think of as "peptides."

Tier 2: The Clinical Pipeline (Strong but Not Yet Approved)

These are peptides in late-stage trials with genuine data behind them — not gray-market compounds, but not yet available by prescription either.

Retatrutide is Eli Lilly's triple agonist, hitting GLP-1, GIP, and glucagon receptors. In its Phase 2 obesity trial, the highest dose produced roughly 24% weight loss at 48 weeks, and Phase 3 (TRIUMPH) is ongoing. It's investigational — not approved, not legitimately available outside a trial. The full picture is in the retatrutide guide.

Cagrilintide is a long-acting amylin analog. On its own it produces moderate weight loss; combined with semaglutide as CagriSema, late-stage trials have shown results competitive with tirzepatide. Also investigational.

The reason these matter for this page: they're peptides, the data is real, and they show the category's momentum is overwhelmingly in the incretin/hormone-analog direction — not the fragment-of-growth-hormone direction the gray market is built on.

Tier 3: The "Research Peptides" Marketed for Fat Loss

This is where the marketing and the evidence diverge hardest. These compounds are sold online — often labeled "for research use only" or "not for human consumption" — with claims that outrun the data.

AOD-9604 is the clearest cautionary tale. It's a fragment of human growth hormone, and it was developed specifically as an anti-obesity drug by a pharmaceutical company. It went through human trials — and its Phase 2 studies did not show meaningful weight loss over placebo. Development for obesity was effectively abandoned. It's now sold as a fat-loss peptide on the strength of a mechanism that didn't pan out in people.

HGH fragment 176-191 is a related growth-hormone fragment marketed on similar "targets fat metabolism" claims. The supporting evidence is mostly animal studies; there's no body of quality human weight-loss trials behind it.

Growth-hormone secretagogues — CJC-1295, ipamorelin, sermorelin, and the oral MK-677 — raise growth hormone and IGF-1. The theory is that more GH means more fat loss. In practice, the human evidence for meaningful fat loss in otherwise-healthy adults is weak and indirect, and raising IGF-1 carries its own considerations. People do use them for body recomposition, and most users report effects on sleep and recovery more than the scale; the mechanism and evidence are covered honestly in the CJC-1295 / ipamorelin guide.

Tesamorelin deserves a careful note because it's the exception that proves the rule. It's a GHRH analog and it is FDA-approved — but specifically to reduce visceral fat in people with HIV-associated lipodystrophy, not for general weight loss. Extrapolating its narrow, approved use into "a peptide for losing weight" is exactly the kind of leap the marketing makes and the evidence doesn't support.

One more clarification, because it shows up in these searches: tesofensine is often lumped in with weight-loss peptides, but it isn't a peptide at all — it's a small-molecule triple monoamine reuptake inhibitor. It has shown weight loss in trials but also raised blood-pressure and cardiovascular concerns, and it's not approved.

How to Read the Gap Between Marketing and Evidence

A few patterns make the gray-market claims easier to evaluate without being an endocrinologist:

• "Targets fat" mechanism ≠ clinical result. AOD-9604 had a plausible fat-metabolism mechanism and still failed its human trials. Mechanism is a hypothesis, not a result.
• Animal data is a starting point, not proof. "Studies show" often means rodent studies. Ask whether there's a human trial measuring actual weight loss.
• Approved-but-narrow gets stretched. Tesamorelin is real and approved — for a specific condition. A narrow approval is routinely marketed as a general one.
• "Research use only" is a tell. It means the compound hasn't been approved for human use and isn't held to pharmaceutical quality standards for purity or dose.

None of this is a judgment about why someone wants to lose weight or what they choose to use. It's about matching expectations to evidence — so the decision is informed rather than sold.

Safety, Sourcing, and Legality

We don't recommend specific protocols, doses, or suppliers — and that's especially true here. A few honest points:

• Quality control varies enormously. Prescription GLP-1s are manufactured to pharmaceutical standards. Gray-market research peptides have no guarantee of purity, sterility, or that the vial contains what the label says.
• Legal status differs by substance and country. Some of these are unapproved drugs; some sit in a research-chemical gray zone. "Available to buy" is not the same as "legal to use" or "safe to use."
• Reconstitution and storage matter. If you are using any lyophilized peptide, mixing and storing it correctly affects both safety and whether it's doing anything at all — see the peptide reconstitution guide and peptide storage guide. The free reconstitution calculator handles the dose math.

The single most useful move for anyone serious about weight loss is to have the conversation with a licensed provider — the evidence-backed options (the GLP-1 peptides) are prescription drugs anyway, and a provider can weigh them against your health rather than a vendor's landing page.

If You're Tracking a Protocol

Whatever you and your provider land on, the thing that actually moves outcomes is consistency and data — dose, timing, injection site, weight trend, and how you feel at each step. That's true whether you're titrating a GLP-1 up to its maintenance dose or running anything else.

Done Dose tracks all of it in one place: dose logging, a visual injection-site rotation map, body metrics over time, and dose-level history so you can see what changed and when. For GLP-1 specifically, pair it with the tirzepatide dose chart or semaglutide dosage chart to know where you are in the schedule; if you're tracking research peptides, the best peptide tracker app comparison covers the options. Set it up in under a minute and stop relying on memory for a protocol that depends on precision.